Ensign Decla­res $0.065 Quar­ter­ly Divi­dend, Main­ta­ins Pay­out Level

Latest divi­dend announce­ment

The Ensign Group, Inc. has declared a quar­ter­ly cash divi­dend of $0.065 per share, main­tai­ning the same level as the pre­vious dis­tri­bu­ti­on. The health­ca­re ser­vices pro­vi­der announ­ced the divi­dend on March 23, 2026.

The divi­dend cor­re­sponds to an annua­li­zed pay­out of $0.26 per share. Based on the cur­rent share pri­ce of appro­xi­m­ate­ly $202.77, the stock offers a for­ward divi­dend yield of rough­ly 0.13%.

The pay­ment is sche­du­led for April 30, 2026. Share­hol­ders must be on record as of March 31, 2026, which also marks the ex-divi­dend date.

Details of the divi­dend dis­tri­bu­ti­on

The latest divi­dend matches the pre­vious quar­ter­ly pay­ment of $0.065, which the com­pa­ny intro­du­ced with the Decem­ber 2025 dis­tri­bu­ti­on. The pay­out the­r­e­fo­re remains sta­ble com­pared with the pri­or quar­ter.

With four quar­ter­ly pay­ments per year, Ensign’s divi­dend poli­cy results in a total annu­al dis­tri­bu­ti­on of $0.26 per share. Alt­hough the abso­lu­te yield remains mode­st rela­ti­ve to tra­di­tio­nal inco­me stocks, the com­pa­ny main­ta­ins a high­ly con­ser­va­ti­ve pay­out struc­tu­re.

The divi­dend pay­out ratio stands at rough­ly 4.3% of ear­nings, based on cur­rent finan­cial data. Such a low pay­out level signals that the com­pa­ny reta­ins the vast majo­ri­ty of its ear­nings for reinvest­ment, acqui­si­ti­ons, and ope­ra­tio­nal expan­si­on.

Rele­vant valua­ti­on metrics

Ensign curr­ent­ly holds a mar­ket capi­ta­liza­ti­on of appro­xi­m­ate­ly $11.8 bil­li­on. The com­pa­ny ope­ra­tes in the medi­cal care faci­li­ties indus­try within the health­ca­re sec­tor.

Seve­ral valua­ti­on indi­ca­tors high­light the company’s growth-ori­en­ted pro­fi­le:

The stock trades at a for­ward pri­ce-to-ear­nings ratio of about 24.6, based on pro­jec­ted ear­nings per share of $8.24. The trai­ling P/E ratio is signi­fi­cant­ly hig­her at around 34.7, reflec­ting strong ear­nings growth expec­ta­ti­ons.

The com­pa­ny gene­ra­tes annu­al reve­nue of appro­xi­m­ate­ly $5.06 bil­li­on, with EBITDA of rough­ly $529 mil­li­on and an EBITDA mar­gin slight­ly abo­ve 10%.

Free cash flow curr­ent­ly totals about $281 mil­li­on, which com­for­ta­b­ly covers the annu­al divi­dend obli­ga­ti­on due to the extre­me­ly low pay­out ratio. Ensign also main­ta­ins solid liqui­di­ty with $572 mil­li­on in cash on the balan­ce sheet.

Enter­pri­se value stands near $13.3 bil­li­on, imply­ing an EV/EBITDA mul­ti­ple of about 25.2, a valua­ti­on typi­cal for health­ca­re ope­ra­tors with strong growth tra­jec­to­ries.

Divi­dend histo­ry and sus­taina­bi­li­ty

Ensign has built a con­sis­tent divi­dend record over the past two deca­des. The com­pa­ny has paid divi­dends for 18 con­se­cu­ti­ve years and achie­ved 18 con­se­cu­ti­ve years of divi­dend growth.

The divi­dend tra­jec­to­ry illus­tra­tes gra­du­al but con­sis­tent increa­ses. Quar­ter­ly pay­outs rose from $0.0102 in 2007 to $0.065 today, repre­sen­ting more than a six­fold increase over the peri­od.

More recent­ly, the com­pa­ny rai­sed the quar­ter­ly divi­dend from $0.058 in 2023 to $0.060 in 2024, fol­lo­wed by $0.063 in ear­ly 2025 and the cur­rent $0.065 level intro­du­ced at the end of 2025.

This ste­ady pro­gres­si­on demons­tra­tes a disci­pli­ned capi­tal allo­ca­ti­on stra­tegy that com­bi­nes growth invest­ments with gra­du­al­ly rising share­hol­der dis­tri­bu­ti­ons.

Becau­se the divi­dend con­su­mes only a small frac­tion of ear­nings, the com­pa­ny reta­ins signi­fi­cant fle­xi­bi­li­ty to con­ti­nue incre­asing the pay­out over time while fun­ding acqui­si­ti­ons and expan­si­on.

Out­look for long-term inves­tors

For long-term inves­tors, Ensign repres­ents a growth-ori­en­ted divi­dend stock rather than a high-yield inco­me vehic­le.

The com­pa­ny con­ti­nues to deli­ver robust ope­ra­ting momen­tum. Reve­nue growth recent­ly excee­ded 20%, while ear­nings growth remains near 18% annu­al­ly. The­se figu­res sug­gest con­tin­ued expan­si­on across its health­ca­re ser­vices plat­form.

Given the mini­mal pay­out ratio, Ensign pos­s­es­ses sub­stan­ti­al capa­ci­ty to increase its divi­dend in future years. If ear­nings growth per­sists, the com­pa­ny could gra­du­al­ly sca­le its dis­tri­bu­ti­ons wit­hout com­pro­mi­sing reinvest­ment or finan­cial sta­bi­li­ty.

Howe­ver, the stock’s cur­rent valua­ti­on reflects the­se growth expec­ta­ti­ons. Inves­tors the­r­e­fo­re rely pri­ma­ri­ly on ear­nings expan­si­on and capi­tal app­re­cia­ti­on, with divi­dends ser­ving as a secon­da­ry but ste­adi­ly gro­wing com­po­nent of total return.

Com­pa­ny pro­fi­le

The Ensign Group, Inc. is a U.S.-based health­ca­re ser­vices pro­vi­der head­quar­te­red in San Juan Capis­tra­no, Cali­for­nia. The com­pa­ny ope­ra­tes a net­work of skil­led nur­sing faci­li­ties, seni­or living com­mu­ni­ties, and reha­bi­li­ta­ti­on ser­vices across mul­ti­ple sta­tes.

Its busi­ness model focu­ses on post-acu­te health­ca­re ser­vices, inclu­ding skil­led nur­sing care, assis­ted living, and spe­cia­li­zed the­ra­py pro­grams. Ensign also owns health­ca­re real estate through affi­lia­ted enti­ties that lea­se pro­per­ties to ope­ra­ting sub­si­dia­ries.

Through a stra­tegy cen­te­red on acqui­si­ti­ons, ope­ra­tio­nal impro­ve­ments, and decen­tra­li­zed manage­ment, Ensign has expan­ded into one of the lar­ger ope­ra­tors in the U.S. post-acu­te care sec­tor.

With strong reve­nue growth, con­ser­va­ti­ve levera­ge, and a long record of divi­dend increa­ses, the com­pa­ny remains posi­tio­ned as a long-term com­poun­der within the health­ca­re ser­vices indus­try.

last quar­ter­ly report*

Sum­ma­ry: The Ensign Group – FY 2025 Annu­al Report

1. Finan­cial Per­for­mance

The Ensign Group repor­ted strong reve­nue and ear­nings growth in 2025.

  • Total reve­nue: $5.06 bil­li­on (2025) vs. $4.26 bil­li­on (2024)
  • Net inco­me: $344.3 mil­li­on (2025) vs. $298.5 mil­li­on (2024)
  • Diluted EPS: $5.84 vs. $5.12 in the pri­or year

Reve­nue increased by rough­ly 18.7% year-over-year, pri­ma­ri­ly dri­ven by hig­her pati­ent occu­p­an­cy, impro­ved reim­bur­se­ment mix, and new­ly acqui­red faci­li­ties.

Ope­ra­ting inco­me rea­ched $425.3 mil­li­on, while net mar­gin was appro­xi­m­ate­ly 6.8% of reve­nue.

2. Key Busi­ness Dri­vers

Growth was main­ly sup­port­ed by expan­si­on in the company’s skil­led nur­sing ope­ra­ti­ons.

Key ope­ra­tio­nal metrics:

  • Skil­led ser­vices reve­nue: $4.84 bil­li­on (+18.7%)
  • Faci­li­ties ope­ra­ted: 326 faci­li­ties (up from 286)
  • Pati­ent days: 10.8 mil­li­on (+14.5%)
  • Occu­p­an­cy rate: 82.2% (up from 80.5%)

Impro­ved occu­p­an­cy and a hig­her share of skil­led-care pati­ents increased reve­nue per pati­ent day and pro­fi­ta­bi­li­ty.

Acqui­si­ti­ons also con­tri­bu­ted meaningful­ly. Recent­ly acqui­red faci­li­ties gene­ra­ted $653 mil­li­on in reve­nue, reflec­ting rapid expan­si­on of the company’s foot­print.

3. Seg­ment Per­for­mance

The com­pa­ny ope­ra­tes pri­ma­ri­ly through two seg­ments:

Skil­led Ser­vices

  • Reve­nue: $4.84 bil­li­on
  • Seg­ment inco­me: $616 mil­li­on

This seg­ment includes skil­led nur­sing faci­li­ties and post-acu­te care ser­vices and remains the domi­nant reve­nue source.

Stan­dard Bea­rer (Real Estate)

  • Ren­tal reve­nue: $126.9 mil­li­on (+33.5%)
  • Funds from ope­ra­ti­ons (FFO): $75.2 mil­li­on (+28.3%)

Growth resul­ted from real-estate acqui­si­ti­ons and rent increa­ses within the company’s health­ca­re pro­per­ty port­fo­lio.

4. Pro­fi­ta­bi­li­ty and Non-GAAP Metrics

Manage­ment also reports seve­ral non-GAAP per­for­mance mea­su­res:

  • EBITDA: $543 mil­li­on
  • Adjus­ted EBITDA: $602 mil­li­on
  • Adjus­ted EBITDAR: $842 mil­li­on

The­se metrics reflect ope­ra­tio­nal pro­fi­ta­bi­li­ty befo­re rent and cer­tain non-recur­ring items and are wide­ly used in the health­ca­re faci­li­ty indus­try.

5. Balan­ce Sheet and Liqui­di­ty

The com­pa­ny main­tai­ned a rela­tively con­ser­va­ti­ve balan­ce sheet.

Key figu­res (end of 2025):

  • Total assets: $5.46 bil­li­on
  • Total equi­ty: $2.23 bil­li­on
  • Long-term debt: about $137.5 mil­li­on

The com­pa­ny also had access to a $600 mil­li­on cre­dit faci­li­ty with no out­stan­ding bor­ro­wings at year-end, pro­vi­ding signi­fi­cant liqui­di­ty fle­xi­bi­li­ty.

Cash and equi­va­lents tota­led $503.9 mil­li­on.

6. Cash Flow

Ope­ra­ting per­for­mance gene­ra­ted strong cash flow.

  • Ope­ra­ting cash flow: $564 mil­li­on
  • Inves­t­ing cash flow: –$513 mil­li­on (main­ly acqui­si­ti­ons and capi­tal expen­dit­ures)

Cash gene­ra­ti­on increased signi­fi­cant­ly com­pared with the pri­or year due to stron­ger ope­ra­ti­ons and impro­ved coll­ec­tions.

7. Share­hol­der Returns

The com­pa­ny has a long divi­dend histo­ry:

  • It has paid divi­dends sin­ce 2002.
  • Divi­dend increa­ses have occur­red every year for 23 con­se­cu­ti­ve years.

In 2025 the com­pa­ny also repurcha­sed $20 mil­li­on of shares under a stock buy­back pro­gram.

8. Over­all Assess­ment

The 2025 results show:

  • Strong reve­nue growth dri­ven by acqui­si­ti­ons and occu­p­an­cy impro­ve­ments.
  • Expan­ding faci­li­ty net­work and pati­ent volu­mes.
  • Healt­hy mar­gins and cash gene­ra­ti­on.
  • Mode­ra­te levera­ge with sub­stan­ti­al liqui­di­ty.

The Ensign Group con­ti­nues to expand its skil­led nur­sing and post-acu­te care plat­form while main­tai­ning a con­sis­tent divi­dend growth record.


*This is the latest quar­ter­ly report that the com­pa­ny has filed with the SEC.

Next Ear­nings Date: 4/28/2026 After clo­se

finviz dynamic chart for ENSG

Die Selek­ti­on die­ser Aktie erfolg­te zufäl­lig aus einem brei­ten Spek­trum an tages­ak­tu­el­len Bör­sen­mit­tei­lun­gen bezüg­lich ange­kün­dig­ter Divi­den­den­zah­lun­gen. Der vor­lie­gen­de Bei­trag zielt nicht auf eine qua­li­ta­ti­ve Bewer­tung die­ser divi­den­den­star­ken Aktie ab, son­dern ver­folgt einen rein deskrip­ti­ven Ansatz.

Was sind Divi­dend Cham­pi­ons, Con­ten­ders, Chal­len­gers?


Wie hilf­reich war die­ser Bei­trag?

Kli­cke auf die Ster­ne um zu bewer­ten!

Durch­schnitt­li­che Bewer­tung 0 / 5. Anzahl Bewer­tun­gen: 0

Bis­her kei­ne Bewer­tun­gen! Sei der Ers­te, der die­sen Bei­trag bewer­tet.

Es tut uns leid, dass der Bei­trag für dich nicht hilf­reich war!

Las­se uns die­sen Bei­trag ver­bes­sern!

Wie kön­nen wir die­sen Bei­trag ver­bes­sern?

Disclaimer: Dieser Beitrag dient lediglich zu allgemeinen Informationszwecken und stellt keine Anlageberatung dar. Bitte konsultieren Sie vor jeder Anlageentscheidung einen unabhängigen Finanzberater